This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Asano, T. Articles by Reddy, S. A.G. Search for Related Content PubMed PubMed Citation Articles by Asano, T. Articles by Reddy, S. A.G.

Insulin Receptor Substrate Is a Mediator of Phosphoinositide 3-Kinase Activation in Quiescent Pancreatic Cancer Cells

¹ Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas and ² Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, North Carolina

Requests for reprints: Shrikanth Reddy, Department of Gastrointestinal Medical Oncology, Unit 426, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-2828; E-mail: sareddy{at}mdanderson.org.

Phosphoinositide 3-kinase (PI3K) is activated in pancreatic cancer cells and plays a central role in their proliferation, survival, and drug resistance. Although the mechanism is unclear, PI3K activation in these cells could be due to physical interaction between its regulatory subunit (p85) and specific tyrosine kinases or their mediators. Consistent with this possibility, PI3K was precipitated with anti-phosphotyrosine antibodies and Akt phosphorylation was blocked by the tyrosine kinase inhibitors SU6656 and PD158780 in quiescent pancreatic cancer cells. Pull-down assays with a fusion protein (GST-p85NC-SH2), and coimmunoprecipitation studies, indicated that the insulin receptor substrate (IRS), and not the epidermal growth factor and insulin-like growth factor receptors or the Src tyrosine kinase, was physically associated with PI3K in these cells. Our data also indicated that SU6656 and PD158780 inhibited Akt activation in pancreatic cancer cells by interfering with the ability of IRS-1 to recruit PI3K. Furthermore, IRS-1 was phosphorylated on a p85-binding site (Y⁶¹²), and IRS-specific small interfering RNA potently inhibited activation of PI3K and Akt in transfected cells. Taken together, these observations indicate that IRS is a mediator of PI3K activation in quiescent pancreatic cancer cells.

This article has been cited by other articles:

				S. Kolb, R. Fritsch, D. Saur, M. Reichert, R. M. Schmid, and G. Schneider HMGA1 Controls Transcription of Insulin Receptor to Regulate Cyclin D1 Translation in Pancreatic Cancer Cells Cancer Res., May 15, 2007; 67(10): 4679 - 4686. [Abstract] [Full Text] [PDF]

				M. Reichert, D. Saur, R. Hamacher, R. M. Schmid, and G. Schneider Phosphoinositide-3-Kinase Signaling Controls S-Phase Kinase-Associated Protein 2 Transcription via E2F1 in Pancreatic Ductal Adenocarcinoma Cells Cancer Res., May 1, 2007; 67(9): 4149 - 4156. [Abstract] [Full Text] [PDF]

				X. Deng, D. Z. Ewton, S. Li, A. Naqvi, S. E. Mercer, S. Landas, and E. Friedman The Kinase Mirk/Dyrk1B Mediates Cell Survival in Pancreatic Ductal Adenocarcinoma. Cancer Res., April 15, 2006; 66(8): 4149 - 4158. [Abstract] [Full Text] [PDF]